Elisabeth Emilsen

519 total citations
17 papers, 428 citations indexed

About

Elisabeth Emilsen is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Elisabeth Emilsen has authored 17 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Immunology. Recurrent topics in Elisabeth Emilsen's work include Melanoma and MAPK Pathways (3 papers), Cell death mechanisms and regulation (3 papers) and interferon and immune responses (2 papers). Elisabeth Emilsen is often cited by papers focused on Melanoma and MAPK Pathways (3 papers), Cell death mechanisms and regulation (3 papers) and interferon and immune responses (2 papers). Elisabeth Emilsen collaborates with scholars based in Norway, United States and Israel. Elisabeth Emilsen's co-authors include Viví Ann Flørenes, Ana Slipicevic, Ruth Holm, Anne Katrine Ree Rosnes, Ben Davidson, Bjørn Risberg, Aasmund Berner, Gunnar Kvalheim, Gunnar B. Kristensen and Øystein Fodstad and has published in prestigious journals such as PLoS ONE, Biochemical and Biophysical Research Communications and International Journal of Cancer.

In The Last Decade

Elisabeth Emilsen

16 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elisabeth Emilsen Norway	10	280	167	80	60	60	17	428
Yanjun Gu China	11	348 1.2×	166 1.0×	208 2.6×	52 0.9×	77 1.3×	24	532
Eslam A. Elghonaimy Egypt	11	241 0.9×	273 1.6×	103 1.3×	36 0.6×	130 2.2×	18	511
Roel H. Wilting Netherlands	4	443 1.6×	130 0.8×	86 1.1×	46 0.8×	41 0.7×	4	547
Jian‐Ming Wen China	9	324 1.2×	175 1.0×	123 1.5×	50 0.8×	73 1.2×	9	515
Guido Hennig Germany	9	333 1.2×	187 1.1×	137 1.7×	44 0.7×	21 0.3×	10	504
Janice M. Mehnert United States	8	303 1.1×	183 1.1×	58 0.7×	36 0.6×	52 0.9×	24	409
Susan Morgan United Kingdom	10	236 0.8×	187 1.1×	55 0.7×	19 0.3×	114 1.9×	18	445
Daniel R. Zweitzig United States	8	360 1.3×	283 1.7×	194 2.4×	103 1.7×	50 0.8×	15	636
Marc Payton United States	10	429 1.5×	269 1.6×	112 1.4×	65 1.1×	34 0.6×	17	613
Liangxian Cao United States	11	510 1.8×	277 1.7×	189 2.4×	60 1.0×	44 0.7×	17	694

Countries citing papers authored by Elisabeth Emilsen

Since Specialization

Citations

This map shows the geographic impact of Elisabeth Emilsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Emilsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Emilsen more than expected).

Fields of papers citing papers by Elisabeth Emilsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Emilsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Emilsen. The network helps show where Elisabeth Emilsen may publish in the future.

Co-authorship network of co-authors of Elisabeth Emilsen

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Emilsen. A scholar is included among the top collaborators of Elisabeth Emilsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Emilsen. Elisabeth Emilsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Flørenes, Viví Ann, Karine Flem‐Karlsen, Vigdis Nygaard, et al.. (2019). A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Translational Oncology. 12(7). 951–958. 10 indexed citations

2.

Nymoen, Dag André, Ana Slipicevic, Arild Holth, et al.. (2016). MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. Human Pathology. 54. 74–81. 8 indexed citations

3.

Emilsen, Elisabeth, Karianne G. Fleten, Birgit Engesæter, et al.. (2015). Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer. 15(1). 462–462. 40 indexed citations

4.

Flørenes, Viví Ann, et al.. (2015). Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma. Cancer Medicine. 4(6). 903–913. 8 indexed citations

5.

Slipicevic, Ana, Anne Katrine Ree Rosnes, Elisabeth Emilsen, et al.. (2013). Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biology & Therapy. 14(2). 146–154. 14 indexed citations

6.

Slipicevic, Ana, Ruth Holm, Elisabeth Emilsen, et al.. (2012). Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival. BMC Cancer. 12(1). 73–73. 1 indexed citations

7.

Hetland, Thea Eline, Dag André Nymoen, Elisabeth Emilsen, et al.. (2012). MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. Gynecologic Oncology. 126(3). 460–465. 25 indexed citations

8.

Rosnes, Anne Katrine Ree, Susan Shahzidi, Hiep Phuc Dong, et al.. (2012). Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma. Biochemical and Biophysical Research Communications. 420(3). 516–522.

9.

Holm, Ruth, et al.. (2012). High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy. PLoS ONE. 7(6). e38254–e38254. 122 indexed citations

10.

Slipicevic, Ana, Ruth Holm, Elisabeth Emilsen, et al.. (2012). Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival. BMC Cancer. 12(1). 73–73. 26 indexed citations

11.

Dong, Hiep Phuc, et al.. (2010). Measurement of apoptosis in cytological specimens by flow cytometry: comparison of Annexin V, caspase cleavage and dUTP incorporation assays. Cytopathology. 22(6). 365–372. 5 indexed citations

12.

Hjortland, Geir Olav, Kristin Bjørnland, Solveig Pettersen, et al.. (2003). Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1. Clinical & Experimental Metastasis. 20(4). 301–309. 25 indexed citations

13.

Lorico, Aurelio, et al.. (2002). Role of the multidrug resistance protein 1 gene in the carcinogenicity of aflatoxin B1: investigations using mrp1-null mice. Toxicology. 171(2-3). 201–205. 18 indexed citations

14.

Berner, Aasmund, et al.. (2001). Cultured anaplastic cell lines as immunocytochemistry controls: A comparison of ThinPrep®‐processed smears and conventional air‐dried cytospins. Diagnostic Cytopathology. 25(5). 303–308. 6 indexed citations

15.

Davidson, Ben, Bjørn Risberg, Gunnar B. Kristensen, et al.. (1999). Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 435(1). 43–49. 91 indexed citations

16.

Rye, Philip D., Øystein Fodstad, Elisabeth Emilsen, & Magne Bryne. (1998). Invasion potential and N-acetylgalactosamine expression in a human melanoma model. International Journal of Cancer. 75(4). 609–614. 26 indexed citations

17.

Karlsen, Frank, et al.. (1997). A novel grid polymerase chain reaction (G-PCR) approach at ultrastructural level to detect target DNA in cell cultures and tissues. The Journal of Pathology. 183(4). 486–493. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact